In response to the limitations of broad immunomodulators like IVIG, more targeted complement therapies have emerged, such as the monoclonal antibody eculizumab, which targets C5 and has been proven effective in conditions like atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (41, 42). This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.